Abstract: Current adversarial attacks pose a serious threat to the robustness of visual-language models (VLMs), including vision-language pre-trained models (VLPMs) and multimodal large language ...
The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...
Before market open, Recursion divulged that its REC-4881 demonstrated notable efficacy in a phase 1b/2 trial. The drug, which treats a disorder called familial adenomatous polyposis (FAP) in which ...
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...
Abstract: This paper introduces an innovative recursive methodology for ultra-fast load flow analysis. The approach is based on the Holomorphic Embedding Load Flow Method (HELM) and employs the Total ...
If only they were robotic! Instead, chatbots have developed a distinctive — and grating — voice. Credit...Illustration by Giacomo Gambineri Supported by By Sam Kriss In the quiet hum of our digital ...
After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback